Table 1.
The schematics of imaging and therapy regimen
| Groups | Day 0 | Day 1 | Day 2 | Day 3 | |
|---|---|---|---|---|---|
| 18F-Alfatide II imaging (40 min vs. 60 min) (U87MG: 7 mice; MDA-MB-435: 8 mice) | |||||
|
| |||||
| 1 | (n = 15) | + | |||
|
| |||||
| 18F-FDG signal recovery validation (U87MG: 6 mice; MDA-MB-435: 8 mice) | |||||
|
| |||||
| 2 | (n=15) | ※ | # | ||
|
| |||||
| Therapy monitoring (U87MG) | |||||
|
| |||||
| 3 | Control (n=4) | # | # | ||
| Treated (n=5) | #, Δ | Δ | # | ||
|
| |||||
| Therapy monitoring (MDA-MB-435) | |||||
|
| |||||
| 4 | Control (n=6) | # | # | ||
| Treated (n=8) | #, ± | ± | # | ||
+ 18F-Alfatide II imaging; ※ 18F-FDG imaging; # 18F-Alfatide II and 18F-FDG dual tracer imaging; Δ Doxorubicin treatment; ± Abraxane treatment